News Archive - GOG

GOG Partners Connection Quarterly Newsletter – April 2026

Lindsey Moeller — Sat, 18 Apr 2026 15:01:43 +0000

The GOG Partners Connection Quarterly Newsletter is now available!

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – April 2026 appeared first on GOG.

Accrual Culture: Top Points for Site Selection – Timelines

Lindsey Moeller — Thu, 02 Apr 2026 22:34:10 +0000

**The GOG’s Accrual Culture series—Top Points for Site Selection—is available now!**

Access this new episode here:

Access on GOG GYN-LIVE Podcast

Access on YouTube

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:
Corecept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem

The post Accrual Culture: Top Points for Site Selection – Timelines appeared first on GOG.

GOg-3073/ENGOT-ov72/ROSELLAPress Release

Lindsey Moeller — Wed, 25 Mar 2026 19:57:35 +0000

PRESS RELEASE

For Immediate Release

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

On March 25, 2026: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).

Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, at least one of which included bevacizumab. Patients were randomized 1:1 to receive either Lifyorli plus nab-paclitaxel or nab-paclitaxel monotherapy. No biomarker selection was required.

Click here to read full Corcept Therapeutics press release.

The post GOg-3073/ENGOT-ov72/ROSELLA
Press Release
appeared first on GOG.

KEYNOTE-B96/ENGOT-ov65Press Release

Lindsey Moeller — Wed, 11 Feb 2026 16:35:11 +0000

PRESS RELEASE

For Immediate Release

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1)

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

FDA also approved the PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Inc) as a companion diagnostic device to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) for treatment with pembrolizumab.

Full prescribing information for Keytruda and Keytruda Qlex will be posted on Drugs@FDA.

Click here to read full FDA news release.

Click here to read full Merck press release.

The post KEYNOTE-B96/ENGOT-ov65
Press Release
appeared first on GOG.

Accrual Culture: Top Points for Site Selection – Enrollement

Lindsey Moeller — Thu, 29 Jan 2026 20:55:41 +0000

**The GOG’s Accrual Culture series—Top Points for Site Selection—is available now!**

Access this new episode here:

Access on GOG GYN-LIVE Podcast

Access on YouTube

The post Accrual Culture: Top Points for Site Selection – Enrollement appeared first on GOG.

GOG GYN-LIVE PODCAST

Lindsey Moeller — Thu, 29 Jan 2026 20:46:57 +0000

The GOG GYN-LIVE Podcast is available now!

Welcome to the official podcast of The GOG Foundation, Inc.—a nonprofit organization dedicated to advancing excellence in clinical and scientific research for gynecologic cancers. From ovarian and uterine to cervical, vaginal, and vulvar malignancies, our investigators and institutions are at the forefront of innovation, shaping the future of cancer care.

Each episode features leading experts, groundbreaking trial insights, and real-world stories that illuminate the evolving landscape of gynecologic oncology. Whether you’re a clinician, researcher, patient advocate, or survivor, join us as we explore the science, the people, and the progress driving better outcomes and quality of life for patients everywhere.

Subscribe and List

Listen to GOG GYN-LIVE using one of many popular podcasting apps or directories.

Subsribe by RSS Feed

Click here to access the GOG GYN-LIVE Podcast website page.

The post GOG GYN-LIVE PODCAST appeared first on GOG.

ROSELLA GOG-3073 | ENGOT-OV72Press Release

Lindsey Moeller — Thu, 22 Jan 2026 21:07:23 +0000

PRESS RELEASE

For Immediate Release

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Jan. 22, 2026– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary endpoint.

Click here to read full press release.

The post ROSELLA GOG-3073 | ENGOT-OV72
Press Release
appeared first on GOG.

GOG Partners Connection Quarterly Newsletter – December 2025

Lindsey Moeller — Tue, 23 Dec 2025 16:55:56 +0000

The GOG Partners Connection Quarterly Newsletter is now available!

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – December 2025 appeared first on GOG.

GOG-3133/ FRAmework-01/ ENGOT-ov97/ GINECO-NOGGO Press Release

Lindsey Moeller — Tue, 09 Dec 2025 20:47:10 +0000

PRESS RELEASE

For Immediate Release

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli Lilly and Company and conducted in collaboration with The GOG Foundation, Inc.

Click here to read full press release.

The post GOG-3133/ FRAmework-01/ ENGOT-ov97/
GINECO-NOGGO Press Release
appeared first on GOG.

GOG Partners Connection Quarterly Newsletter – September 2025

Lindsey Moeller — Thu, 16 Oct 2025 18:09:47 +0000

The GOG Partners Connection Quarterly Newsletter is now available!

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – September 2025 appeared first on GOG.